Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Castle BiosciencesCSTL +2.54%79 EV-to-EBITDA is -217.78 as of Jul. 24, 2026. GuruFocus rates CSTL with a GF Score™ of 79/100 and a GF Value™ of $29.22 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Castle Biosciences ranks worse than 854700% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Castle Biosciences's enterprise value is $548.1 Mil.
Castle Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.5 Mil. Therefore, Castle Biosciences's EV-to-EBITDA for today is -217.78.
The historical rank and industry rank for Castle Biosciences's EV-to-EBITDA or its related term are showing as below:
CSTL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -222.97 Med: -3.36 Max: 8463.36
Current: -217.78
During the past 9 years, the highest EV-to-EBITDA of Castle Biosciences was 8463.36. The lowest was -222.97. And the median was -3.36.
CSTL's EV-to-EBITDA is ranked worse than 100% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.61
vs CSTL: -217.78
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Castle Biosciences's PE Ratio (TTM) for today is calculated as:
Castle Biosciences's share price for today is $25.49.
Castle Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Castle Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Castle Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's EV-to-EBITDA falls into.
Castle Biosciences's current Enterprise Value is $548.1 Mil.
Castle Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a EV-to-EBITDA of -217.78 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Castle Biosciences. According to the industry distribution chart, Castle Biosciences ranks #999999 out of 117 companies in the Medical Diagnostics & Research industry.
Is Castle Biosciences' EV-to-EBITDA too high?
Castle Biosciences' current EV-to-EBITDA is -217.78. Based on the distribution chart, Castle Biosciences ranks #999999 out of 117 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Castle Biosciences has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' EV-to-EBITDA compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #999999 out of 117 companies for EV-to-EBITDA. This places Castle Biosciences in the lower half of its industry. The industry median EV-to-EBITDA is 14.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.61, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Castle Biosciences. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current EV-to-EBITDA is -217.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.22, compared to a current price of $25.49 — trading 12.8% below its estimated fair value. The current EV-to-EBITDA is -217.78. Castle Biosciences' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current EV-to-EBITDA is -217.78 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of $25.49 is trading 12.8% below its estimated GF Value™ of $29.22.
GuruFocus considers Castle Biosciences to be Modestly Undervalued.
Key valuation signals for CSTL:
EV-to-EBITDA: -217.78
GF Value™: $29.22 vs. price of $25.49 (12.8% below fair value)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
79GF Score
Get the complete analysis for CSTL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
